The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

white-paper
Strategies for Accelerated CMC Development
Read More

case-study
Syner-G Helps Biotech Firm Successfully Advance Life-Saving Drug Through Manufacturing Startup and Clinical Trials
Read More

case-study
Advancing Biotech Drug Development: Syner-G BioPharma’s Collaborative Approach to Chemistry, Manufacturing, and Controls
Read More

case-study
Synthesizing Success: Syner-G’s Strategic Solutions for Elevating a Biotech Innovator
Read More
Let's move from science to success.
Let’s Talk